Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
Why the study?
Does elevated Lipoprotein(a) predict adverse cardiovascular outcomes and extent of angiographic disease in patients undergoing coronary angiography?
Population
2,769 patients who underwent coronary angiography
Comparison
Elevated Lipoprotein(a) levels (≥30 mg/dl) vs Non-elevated Lipoprotein(a) levels (<30 mg/dl)
Design
Cohort
Follow-up
3 years
Authors
Discussion
Loading...
Member takes
Implication
May refine post-angiography risk stratification; leaves open whether Lp(a) lowering reduces revascularization.
Structured PICO
Does elevated Lipoprotein(a) predict adverse cardiovascular outcomes and extent of angiographic disease in patients undergoing coronary angiography?
P
Population
2,769 patients who underwent coronary angiography
I
Intervention
Elevated Lipoprotein(a) levels (≥30 mg/dl)
C
Comparator
Non-elevated Lipoprotein(a) levels (<30 mg/dl)
O
Outcome
3-year incidence of major adverse cardiovascular events (MACE: death, myocardial infarction, stroke, and coronary revascularization)composite
Elevated Lp(a) levels correlate with the extent of obstructive coronary disease and predict the need for coronary revascularization, particularly in patients with suboptimal LDL-C control.
Cite This Study
Nicholls et al. (2010) studied this question.